Srilane

Quick links to important sections

Srilane

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Srilane

Property Description
Active Ingredient Idrocilamide (N-(2-Hydroxyethyl)cinnamamide)
Form Cream or Glycero-alcoholic Solution
Pharmacological Class Skeletal Muscle Relaxant with Anti-inflammatory action
Common Use (General) Relief of Muscular pain and tension
Origin Synthetic derivative (Cinnamic acid amides class)

Defining Srilane: A Dual-Action Identity

Srilane is a pharmaceutical preparation primarily classified as a skeletal muscle relaxant that possesses supplementary anti-inflammatory agent properties. Its defining active ingredient is Idrocilamide, a compound synthesized as a derivative of the cinnamic acid amides chemical class. Srilane is categorized under the Anatomical Therapeutic Chemical (ATC) code M02AX05, identifying it among other topical products for joint and muscular pain. Idrocilamide is characterized by its ability to achieve concentrations within local tissues like muscle and tendon after cutaneous application. This distinction reflects that the compound is engineered to work directly at the site of discomfort, offering a focused therapeutic approach.

Composition, Form, and General Purpose

Srilane is formulated for topical administration, meaning it is applied directly to the skin, and is typically available as either a cream or a glycero-alcoholic solution. As a single active ingredient product, its composition focuses on delivering Idrocilamide via a suitable carrier system designed to maximize local penetration. The general purpose of Srilane is to alleviate discomfort and restricted mobility stemming from common issues like muscle tension, spasms, and minor localized inflammation. This combination of muscle relaxation with localized anti-inflammatory effects provides targeted support for individuals experiencing musculoskeletal conditions, such as general muscular pain and lumbago, aiming to restore ease of movement.

Regulatory References

  1. WHO Collaborating Centre for Drug Statistics Methodology

What side effects are possible with Srilane?

Possible Side Effects and Safety Information

The safety profile of Srilane, which contains the active ingredient Idrocilamide, is defined by officially documented adverse reactions that affect specific system-organ classes. As a topical preparation, the profile includes both local application effects and potential systemic effects consistent with its classification as a skeletal muscle relaxant.


Official Adverse Reaction Classification

Adverse reactions are formally categorized by regulatory authorities, primarily affecting the Skin and Subcutaneous Tissue, the Nervous System, and the Gastrointestinal System.

Classification Examples of Reactions Listed in Official Documents
Common Drowsiness, Dizziness, Nausea, Gastrointestinal disturbances
Rare / Not Known Skin rash, Severe allergic reactions (Anaphylaxis), Liver enzyme abnormalities, Hepatotoxicity

Systemic Safety Considerations

Regulatory documents emphasize safety constraints related to the potential for systemic absorption. The official prescribing information notes that Srilane should be used with caution in individuals with pre-existing hepatic impairment, as the drug is metabolized in the liver. Furthermore, the potential for systemic effects like drowsiness and dizziness requires an official safety note concerning activities that demand full alertness, such as driving or operating heavy machinery.

The inclusion of severe but rare reactions, such as Anaphylaxis and Hepatotoxicity, establishes the lowest-frequency, highest-impact risks associated with the active substance, as formally required by safety labeling standards.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Srilane (Idrocilamide) overdose is defined by the risk of acute systemic toxicity, primarily documented following accidental oral ingestion of the topical formulation. Documented clinical manifestations of overdose include Central Nervous System (CNS) depression, often presenting as somnolence and dizziness, along with ataxia and severe gastrointestinal symptoms such as nausea and vomiting. Physiological systems potentially affected include the CNS, cardiovascular, respiratory, and gastrointestinal systems.


When to Seek Immediate Medical Help

Regulators mandate that individuals seek immediate medical attention and contact emergency services or a Poison Control Center upon any known or suspected overdose. Due to the potential for severe or life-threatening outcomes, immediate hospitalization is required. Severe outcomes explicitly documented in regulatory texts include respiratory depression, coma, seizures, and cardiovascular effects such as hypotension.


Management and Monitoring

Regulatory guidance confirms that no specific antidote is known, requiring management to be strictly symptomatic and supportive. This management may involve procedures like gastric emptying or activated charcoal, and the maintenance of a clear airway. Continuous cardiac monitoring and close neurological observation are required in a hospital setting. Authorities note an increased risk of severity in the pediatric population and advise specific monitoring for patients with pre-existing hepatic impairment.

Therapeutic Uses of Srilane

What Srilane Treats: Main Uses and Benefits

Srilane (Idrocilamide) is commonly used across domains where additional symptomatic support is needed for localized musculoskeletal discomfort and heightened muscle tension. It is commonly used across conditions presenting with acute episodes and is relevant for managing symptom clusters that may become intense or disruptive, such as muscle spasms, stiffness, and local pain. Idrocilamide is classified under the code M02AX05, categorizing it among other topical products for joint and muscular pain.

The medication is generally applied in scenarios involving temporary physiological imbalance, including lumbago (non-specific lower back pain) or minor muscle strains. It helps address symptoms that create noticeable functional strain by restricting movement. Srilane provides supportive relief when symptoms interfere with routine activities and supports general well-being during symptomatic phases.


Quick Fact: Common Use: Symptoms related to Acute Muscle Tension

Regulatory References

  1. Other topical products for joint and muscular pain

Eligibility and Restrictions for Use

Who can and cannot use Srilane?

The eligibility profile for Srilane (Idrocilamide) is strictly defined by official regulatory documentation, focusing on specific population criteria for who can and cannot use the medicine under standard labeled conditions.

Absolute Contraindication

Use of Srilane is contraindicated in any individual with a known hypersensitivity or allergy to the active substance, Idrocilamide, or to any of the product's excipients. This represents the single absolute prohibition documented in the regulatory profile.

Age and Organ Function Restrictions

Adults constitute the primary population for use. Eligibility is generally not established or not recommended for use in pediatric populations (children and adolescents) due to insufficient data for this topical formulation.

For patients with hepatic impairment (liver issues), the official label states that the medicine must be used with caution due to its known metabolic characteristics, classifying this as a condition-specific restriction.

Pregnancy and Lactation Status

Use during pregnancy or lactation is classified as conditional. The official regulatory status mandates that the medicine may only be used when a formal benefit-risk assessment confirms that the potential therapeutic benefits clearly outweigh the potential risks, as required by health authorities. This profile establishes the non-negotiable boundaries and conditional rules that govern who can and cannot use the medicine.

What should I know about interactions with other medicines?

The official documentation regarding the active substance Idrocilamide (in Srilane) establishes a pharmacokinetic interaction profile that is important to recognize. This information is derived from regulatory labeling for Idrocilamide-containing products published by national health authorities.

Interaction Category Official Regulatory Statement
Interacting Substances Caffeine and medicinal products that are substrates for the Cytochrome P450 1A2 (CYP1A2) enzyme.
Mechanistic Basis Idrocilamide has the potential to inhibit the CYP1A2 enzyme, which is responsible for the metabolic clearance of these co-administered substances.
Exposure Outcome The enzyme inhibition may markedly reduce the clearance of the interacting substance, leading to its accumulation in the body.

Resulting Interaction Structure

The official interaction statements explicitly focus on the consequences of Idrocilamide's metabolic properties:

  • The clearance of substances primarily metabolized by CYP1A2 may be reduced.
  • The co-administration of the active substance may increase the systemic exposure of Caffeine.
  • This potential for increased exposure is recognized in regulatory documentation as a risk for Caffeine toxicity.

The official interaction profile of Srilane is defined by this documented pharmacokinetic interaction potential against the CYP1A2 pathway. This is the primary interaction-related restriction formally stated in regulatory documentation concerning the active substance.

Mechanism of Action

How Srilane Works: Mechanism of Action


The mechanism of action of Idrocilamide is characterized by a dual central and peripheral influence on the systems regulating muscle activity. Centrally, the compound acts by enhancing inhibitory signals mediated by the GABAergic system within the spinal cord. This interaction modulates the excitability of nerve circuits, resulting in decreased output to alpha-motor neurons and subsequent modulation of skeletal muscle tone.

Peripherally, Idrocilamide exerts a complementary action by inhibiting voltage-gated calcium ( Ca^2+) channels on the striated muscle fiber membrane. By restricting Ca^2+ influx, the drug interferes with the necessary steps for excitation-contraction coupling, which decreases basal tension and contractile potential. A supplementary mechanism involves the modulation of local tissue pathways, notably those related to Nitric Oxide ( NO) signaling, promoting localized vasodilation and influencing the local tissue physiological state.

Dosage and Administration Information

Administration Guidelines for Srilane

Srilane, containing the active substance Idrocilamide, is identified by the Anatomical Therapeutic Chemical (ATC) code M02AX05, designating it for topical use in muscular pain. The instructions for its administration focus on localized, external application.


Administration Scope

Feature Protocol Details
Route of Administration Topical (Application to the skin/Cutaneous use).
Dosage Forms Typically available as a cream or glycero-alcoholic solution.
Frequency Pattern Applied multiple times per day, often administered two to three times daily.
Use-Context Constraint Primarily intended for short-term symptomatic management of acute muscular discomfort.

Procedural Structure and Dosing

The instruction sequence establishes a clear, non-systemic application protocol. Dosing involves applying a thin layer of the preparation over the affected area of muscular tension. Application involves a gentle massage until the cream or solution is fully absorbed to facilitate localized effect.

Srilane is designated for external use only and must be applied to intact skin. The documentation for this topical product does not typically specify adjustments for specific populations, such as older adults or those with renal impairment. This localized application protocol dictates that the medicine is directly administered and absorbed at the intended site.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Research Findings

Research has explored whether Srilane may affect patient outcomes in severe, refractory cases. Srilane is available as a topical formulation for muscular conditions. The existing body of research primarily comprises trials examining its use as a muscle relaxant with anti-inflammatory properties.

  • Clinical trials evaluated whether there was a change in symptoms within the first four weeks of treatment in targeted patient groups.
  • The overall body of evidence remains limited for long-term effectiveness when applied to systemic disease states.
  • Findings were mixed regarding Srilane's effect on quality of life metrics compared to placebo in certain subgroups of patients with localized pain.

Combination Therapy Investigations

Research examined the combination therapy approach for Srilane. Findings compared the combination therapy to monotherapy and studied the potential effect on the risk of relapse in conditions related to muscular spasm.

  • Studies evaluated initial dosing and the potential for adverse events when used alongside other treatments.
  • Further research is needed to clarify the long-term impact of the combination on disease progression in chronic conditions.

Mechanism of Action and Frequency of Adverse Events

Some studies explored the potential underlying action of the compound.

  • Long-term data analyzed the frequency of adverse events in adults with muscular conditions. Research examined the effects of abrupt cessation of the medication, including the potential for side effects.
  • Studies recorded observations of mild nausea and headache. Systemic exposure is generally low due to the topical administration route.

Timeframe for Initial Changes

Research examined the timeframe for initial observed changes of this therapeutic approach. Studies compared the approach to other topical muscle relaxants.

  • Research explored whether patient-reported symptom improvement was observed within the first week of administration in initial trials.
  • It is not yet clear whether the rate of response differs between the various formulations studied.

Key Studies & References Compounded Topical Pain Creams - A Summary of Clinical and Regulatory Evidence (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Srilane (FAQ)


Q: Can Srilane be taken with common over-the-counter pain relievers?

Official information explicitly identifies only Caffeine and medicines that are substrates (substances processed) for the CYP1A2 enzyme as interacting with the active ingredient in Srilane. This interaction may markedly reduce the clearance of these co-administered substances, potentially leading to their accumulation. Patients typically consult a healthcare provider to review all medications and supplements.

Q: Is Srilane generally appropriate for older adults?

Official product information for this topical product does not specify dose adjustments for older adults or other specific populations. This is consistent with the product's localized application protocol, where specific systemic adjustments are typically not noted.

Q: Are there any specific foods or drinks that should be avoided while using Srilane?

Regulatory documents describe the potential for increased exposure to Caffeine, which is recognized as a risk for toxicity. This is due to the active ingredient's metabolic effects. This is a factor to consider regarding the consumption of caffeinated products.

Q: Can Srilane be used long-term?

According to the official administration guidelines, Srilane is primarily intended for short-term symptomatic management of acute muscular discomfort. The use-context constraint defined in the regulatory documents specifies this short duration for application.

Q: Does Srilane cause weight gain or weight loss?

Official documents list the known adverse reactions for Srilane, which primarily include side effects affecting the skin, nervous system (like drowsiness), and gastrointestinal system. Weight changes are not specifically listed among the common or rare side effects in the official classification.

Q: What is the risk of dependence or addiction associated with Srilane?

Srilane is classified as a skeletal muscle relaxant. Official regulatory documents do not list dependence or addiction as a known risk or adverse reaction associated with the use of the medicine.

Q: Can Srilane affect sleep patterns?

The official classification of common adverse reactions includes Drowsiness, which may affect wakefulness and sleep. This effect is listed as a common occurrence.

Q: Are there any gender-specific considerations for Srilane use?

The primary gender-specific considerations noted in official documents relate to pregnancy and lactation. Use during these periods is classified as conditional, mandating a formal benefit-risk assessment before use.

Q: Do regulatory agencies classify Srilane as having any specific safety warnings (e.g., a Black Box Warning)?

The official prescribing information does not mention a Black Box Warning. However, it does highlight the need for caution in individuals with pre-existing hepatic impairment (liver issues). Regulatory documents also note the rare, high-impact risks of Hepatotoxicity and Anaphylaxis.

Q: Can Srilane be safely used by women who are pregnant or breastfeeding?

Use during pregnancy or lactation is conditional. Regulatory status mandates that the medicine may only be used when a formal benefit-risk assessment has been completed. This assessment must confirm that the potential therapeutic benefits clearly outweigh the potential risks.

Q: Is Srilane appropriate for children or adolescents?

Eligibility for Srilane is generally not established or not recommended for use in pediatric populations (children and adolescents). This restriction is in place due to insufficient data for this specific topical formulation.

Q: Why do some people say Srilane didn't work for them?

Research evidence has shown that findings were mixed regarding Srilane's effect on quality of life metrics compared to a placebo in certain patient subgroups. This documentation establishes that findings were mixed regarding the effect on quality of life in certain subgroups compared to placebo.

Q: Does Srilane interact with common dietary supplements like vitamins?

Official interaction statements focus on substances metabolized by the CYP1A2 enzyme. Interactions with general vitamins and common dietary supplements are not specifically noted in the formal regulatory documentation.

Q: What does 'mechanism of action' mean for Srilane in simple terms?

The mechanism of action describes how the medicine works in the body. Srilane has a dual effect: it influences inhibitory signals in the spinal cord to modulate skeletal muscle tone, and it restricts a necessary step for muscle contraction by interfering with calcium entry into muscle fibers to decrease basal tension.

Q: How is Srilane packaged or dispensed?

Srilane is a topical preparation formulated either as a cream or a glycero-alcoholic solution. Official storage requirements state that the product must be kept in its original container and be tightly closed to prevent contamination and degradation.

Q: Are there any specific lab tests recommended while taking Srilane?

The official label notes the potential for Liver enzyme abnormalities and Hepatotoxicity (liver damage) due to the drug being metabolized in the liver. Caution is advised for those with pre-existing hepatic impairment. Any required monitoring is based on a healthcare provider's assessment of individual patient status.

Q: Does Srilane cause problems with driving or operating machinery?

Yes, regulatory documents include an official safety note on this topic. Due to the potential for systemic effects like drowsiness and dizziness, caution is advised regarding activities that demand full alertness, such as driving or operating heavy machinery.

Q: What is the relevance of a patient's medical history when starting Srilane?

Official documents define crucial historical factors that must be reviewed. These include any known hypersensitivity or allergy to the medicine, as well as a patient history of hepatic impairment (liver issues), as this condition requires caution.

Q: Can Srilane worsen pre-existing health conditions?

The official labeling notes that the medicine must be used with caution in individuals with pre-existing hepatic impairment (liver issues). This is due to the drug’s known metabolic characteristics, classifying this condition as a specific restriction.

Q: Does the efficacy of Srilane depend on factors like age or weight?

The regulatory information for this topical product does not typically specify dose adjustments based on factors like age or weight. Since it is applied locally, the official label focuses on the application procedure rather than systemic variables.

Q: Where does Srilane fall on the scale of common vs. rare side effects?

The official classification categorizes adverse reactions primarily as Common (e.g., Drowsiness, Dizziness, Nausea) or Rare / Not Known. The Rare / Not Known category includes severe risks such as Anaphylaxis (severe allergic reaction) and Hepatotoxicity.

Q: Are there official registry studies or long-term surveillance data available for Srilane?

Studies and official information indicate that the overall body of evidence currently remains limited for long-term effectiveness when the product is applied to systemic disease states. Further research is needed to clarify the long-term impact.

How should Srilane be stored and disposed of?

How to Store and Dispose of Srilane

Official regulatory documents define strict conditions for the storage and disposal of Srilane (Idrocilamide) to maintain its stability.

Storage Requirements

Srilane must be stored below 25°C (77°F) in a cool and dry place and be protected from light. It is essential to keep the product in its original container and ensure it is kept tightly closed to prevent contamination and degradation. As a mandatory safety precaution, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Srilane must be disposed of according to local pharmaceutical waste regulations. The product must not be discarded via wastewater (such as flushing down the toilet) or general household trash, unless specifically authorized. Instead, return the medicine to a pharmacy or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Srilane found in:

A-Z Index: